OncoC4, Inc.

BioNTech is striving to be a major player in immuno-oncology as it further develops its pipeline of bispecific antibodies, CAR-T cell therapies and antibody-drug conjugates (ADC), with one of the bisp

The US Food and Drug Administration has put on partial hold a Phase III study of BioNTech and OncoC4 ’s lead cancer asset BNT316/ONC-392 (gotistobart) after a possible variance in outcomes between

BioNTech has seen its share price rise by 25% in the last few days, buoyed by new investor belief in its emerging cancer drugs pipeline. The revival was sparked by a handful of promising updates at t

BioNTech suffered from plummeting COVID-19 vaccine sales in the first quarter and recorded a loss of €315m ($339m) but is convinced that its investment in novel cancer therapies will pay off soon. On